Samuel J. McConkey

Samuel J. McConkey

Auto-generated profile, based on publicly available information

Samuel J. McConkey

Medical Research Council Laboratories, Fajara, The Gambia

Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 May 2003 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
SMSamuel J McConkey
Samuel J McConkey
WRWilliam H H Reece
William H H Reece
VMVasee S Moorthy
Vasee S Moorthy
DWDaniel Webster
Daniel Webster
SDSusanna Dunachie
Susanna Dunachie
AHAdrian V S Hill
Adrian V S Hill

21 March 2005 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
DWDaniel P. Webster
Daniel P. Webster
SDSusanna Dunachie
Susanna Dunachie
JVJenni M. Vuola
Jenni M. Vuola
TBTamara Berthoud
Tamara Berthoud
SKSheila Keating
Sheila Keating
AHAdrian V. S. Hill
Adrian V. S. Hill
Malaria is a major global health problem for which an effective vaccine is required urgently. Prime-boost vaccination regimes involving plasmid DNA and recombinant modified vaccinia virus Ankara-encoding liver-stage malaria antigens have been shown to be powerfully immunogenic for T cells and capable of inducing partial protection against experimental malaria challenge in humans, manifested as a delay in time to patent parasitemia. Here, we report that substitution of plasmid DNA as the priming vector with a specific attenuated recombinant fowlpox virus, FP9, vaccine in such prime-boost regimes can elicit complete sterile protection that can last for 20 months. Protection at 20 months was associated with persisting memory but not effector T cell responses. The protective efficacy of various immunization regimes correlated with the magnitude of induced immune responses, supporting the strategy of maximizing durable T cell immunogenicity to develop more effective liver-stage vaccines againstPlasmodium falciparummalaria.

21 November 2012 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
TGThe Mind Exchange Working Group
The Mind Exchange Working Group
AAAndrea Antinori
Andrea Antinori
GAGabriele Arendt
Gabriele Arendt
IGIgor Grant
Igor Grant
SLScott Letendre
Scott Letendre
ADAlicia Wiercińska Drapato
Alicia Wiercińska Drapato
Many practical clinical questions regarding the management of human immunodeficiency virus (HIV)–associated neurocognitive disorder (HAND) remain unanswered. We sought to identify and develop practical answers to key clinical questions in HAND management. Sixty-six specialists from 30 countries provided input into the program, which was overseen by a steering committee. Fourteen questions were rated as being of greatest clinical importance. Answers were drafted by an expert group based on a comprehensive literature review. Sixty-three experts convened to determine consensus and level of evidence for the answers. Consensus was reached on all answers. For instance, good practice suggests that all HIV patients should be screened for HAND early in disease using standardized tools. Follow-up frequency depends on whether HAND is already present or whether clinical data suggest risk for developing HAND. Worsening neurocognitive impairment may trigger consideration of antiretroviral modification when other causes have been excluded. The Mind Exchange program provides practical guidance in the diagnosis, monitoring, and treatment of HAND.

1 November 2005 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
SKSheila M. Keating
Sheila M. Keating
PBPhilip Bejon
Philip Bejon
TBTamara Berthoud
Tamara Berthoud
JVJenni M. Vuola
Jenni M. Vuola
Stephen TodrykStephen Todryk
Stephen Todryk
AHAdrian V. S. Hill
Adrian V. S. Hill
Immunological memory is a required component of protective antimalarial responses raised by T cell-inducing vaccines. The magnitude of ex vivo IFN-γ T cell responses is widely used to identify immunogenic vaccines although this response usually wanes and may disappear within weeks. However, protection in the field is likely to depend on durable central memory T cells that are not detected by this assay. To identify longer-lived memory T cells, PBMC from malaria-naive vaccinated volunteers who had received prime boost vaccinations with a combination of DNA and/or viral vectors encoding the multiepitope string-thrombospondin-related adhesion protein Ag were cultured in vitro with Ag for 10 days before the ELISPOT assay. Ex vivo T cell responses peaked at 7 days after the final immunization and declined substantially over 6 mo, but responses identified after T cell culture increased over the 6-mo period after the final immunization. Moreover, individual cultured ELISPOT responses at the day of challenge time point correlated significantly with degree of protection against malaria sporozoite challenge, whereas ex vivo responses did not, despite a correlation between the peak ex vivo response and magnitude of memory responses 6 mo later. This cultured assay identifies long-lasting protective T cell responses and therefore offers an attractive option for assessments of vaccine immunogenicity.

1 June 2006 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
Michiel A. J. van de SandeMichiel A. J. van de Sande
Michiel A. J. van de Sande
PWP. Waight
P. Waight
MMM. Mendy
M. Mendy
PRP. Rayco‐Solon
P. Rayco‐Solon
PHP. Hutt
P. Hutt
HWH. C. Whittle
H. C. Whittle
BackgroundCarriage of hepatitis B virus (HBV) is a major risk factor for liver cirrhosis and hepatocellular carcinoma. Infant vaccination has been ef

5 January 2010 in Journal of Viral Hepatitis
Verified
Journal Article
Open access
PDF file
MMM. E. Mendy
M. E. Mendy
TWT. Welzel
T. Welzel
OLO. A. Lesi
O. A. Lesi
PHP. Hainaut
P. Hainaut
AHA. J. Hall
A. J. Hall
GKG. D. Kirk
G. D. Kirk
Summary. The main objectives of this study were to define the occurrence and levels of hepatitis B virus (HBV) DNA in asymptomatic HBV carriers, cirrhosis patients and hepatocellular carcinoma (HCC) cases from The Gambia, and to evaluate the risk for cirrhosis or HCC associated with HBV viremia. We used sensitive real-time quantitative PCR assays to measure HBV DNA in samples from a case–control study consisting of 60 asymptomatic HBV carriers, 53 cirrhotic patients and 129 HCC cases. Logistic regression was used to estimate the risks of cirrhosis and HCC associated with HBV-DNA levels and HBV e antigenemia (HBeAg) detection (a surrogate marker for viral replication). Detectable HBV viremia and HBeAg positivity were both significantly associated with cirrhosis (increasing risk by fourfold and 11-fold respectively) and with HCC (increasing risk by sixfold and threefold respectively). HBV-DNA levels were significantly higher in both HCC cases and cirrhotic patients compared to asymptomatic carriers (P < 0.01 for both). High-level HBV DNA (>10 000 copies/mL) was strongly associated with both HCC and cirrhosis (17- and 39-fold increased risk). Lower level HBV viremia (200–10 000 copies/mL) conferred a significant risk of HCC, although the association with cirrhosis was not significant. In conclusion, we find that high HBV-DNA levels are strongly associated with the serious sequelae of HBV infection, independent of HBeAg status. While risk for cirrhosis and for HCC notably increases at HBV-DNA levels ≥10 000 copies/mL, low-level viremia was also associated with significant risk for HCC.